Results 31 to 40 of about 119,169 (307)

Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity

Cancer Science, 2023
AbstractCombination therapy with anti‐cytotoxic T lymphocyte‐associated protein 4 (CTLA‐4) and anti‐programmed death‐1 (PD‐1) monoclonal antibodies (mAbs) has dramatically improved the prognosis of patients with multiple types of cancer, including renal cell carcinoma (RCC).
Tomofumi Watanabe, Takamasa Ishino, Youki Ueda, Joji Nagasaki, Takuya Sadahira, Hiromichi Dansako, Motoo Araki, Yosuke Togashi   +7 more
openaire   +3 more sources

The Cytotoxic T Lymphocyte Antigen-4+49A/G Single Nucleotide Polymorphism Association With Visceral Leishmaniasis [PDF]

, 2014
Background: Several lines of evidence approve that innate and adaptive immunity play key roles in the defense against visceral leishmaniasis (VL).
Gomes NA, Goto H, Herwaldt BL, Linsley PS, Meinecke CK, Mohebali M, Murphy ML, Murray HW, Newlove T, Uzer E   +9 more
core   +1 more source

Polymorphism analysis of the CTLA-4 gene in paracoccidioidomycosis patients [PDF]

, 2011
The CTLA-4 protein is expressed in activated T cells and plays an essential role in the immune response through its regulatory effect on T cell activation.
Alfredo M Goes, Anamelia L Bocca, Balbi G, Barreto M, Barrett JC, Blomhoff A, Bocca AL, Bozzi A, Bozzi A, Butty V, Campanelli AP, Carvalho A, Cavassani KA, Dariavach P, Deichmann K, Franco M, Ghaderi A, Goldstein DB, Gough SC, Guzman VB, Han S, Harper K, Holopainen P, Izabel Cristina R Silva, Kouki T, Kristiansen OP, Lee YH, Ligers A, Ling V, Lins TC, Lins TC, Lins TC, Marcus M Teixeira, Maria Heloisa SL Blotta, Maria Sueli S Felipe, Martins GA, Moreno Lima R, Nisticò L, Pritchard JK, Restrepo A, Rinaldo W Pereira, Rodrigo G Vieira, Rosenberg NA, Silva CL, Smith MW, Su TH, Thio CL, Tomer Y, Tulio C Lins, Ueda H, van Belzen MJ, Viviane F Lozano, Wang XB, Yanagawa T, Zaletel K   +54 more
core   +4 more sources

Potent Inhibition of CTLA-4 Expression by an Anti-CTLA-4 Ribozyme

Biochemical and Biophysical Research Communications, 1998
Blockading the negative-regulatory CTLA-4 receptor has emerged as a powerful strategy with clinical potential to enhance T-cell responses. Some experimental tumors, for example, are rejected when anti-CTLA-4 antibodies are administered in vivo. The concise target cells and downstream events, however, remain to be defined.
E, Cepero, H J, Hnatyszyn, G, Kraus, M G, Lichtenheld   +3 more
openaire   +2 more sources

Anti-CTLA-4 Therapy for Malignant Mesothelioma [PDF]

Immunotherapy, 2017
Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1.
Guazzelli, A, Bakker, EY, Krstic-Demonacos, M, Lisanti, MP, Sotgia, F, Mutti, L   +5 more
openaire   +2 more sources

Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. [PDF]

, 2020
BackgroundCTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire.
Cham, Jason, Fong, Grant, Fong, Lawrence, He, Tao, Kwek, Serena, Oh, David Y, Paciorek, Alan, Zhang, Li   +7 more
core   +1 more source

Peptide Blocking CTLA-4 and B7-1 Interaction

Molecules, 2021
Discovery of the B7 family immune checkpoints such as CTLA-4 (CD152), PD-1 (CD279), as well as their ligands B7-1 (CD80), B7-2 (CD86), B7-H1 (PD-L1, CD274), and B7-DC (PD-L2, CD273), has opened new possibilities for cancer immunotherapy using monoclonal ...
Stepan V. Podlesnykh, Kristina E. Abramova, Anastasia Gordeeva, Andrei I. Khlebnikov, Andrei I. Chapoval   +4 more
doaj   +1 more source

Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis [PDF]

, 2009
Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities.
Clatworthy, Menna R, Farrington, Ken, Jolly, Elaine C, Lawrence, Christopher, Nathan, Paul D   +4 more
core   +2 more sources

The gut microbiota and immune checkpoint inhibitors. [PDF]

, 2018
Although immunotherapy has been remarkably effective across multiple cancer types, there continues to be a significant number of non-responding patients. A possible factor proposed to influence the efficacy of immunotherapies is the gut microbiome.
Daud, Adil, Humphries, Audrey
core   +1 more source

CTLA-4 and PD-1 ligand gene expression in epithelial thyroid cancers [PDF]

, 2018
The dysregulation of PD-1 ligands (PD-L1 and PD-L2) and CTLA-4 ligands (CD80 and CD86) represents a tumor strategy to escape the immune surveillance. Here, the expression of PD-L1, PD-L2, CD80 and CD86 was evaluated at mRNA level in 94 patients affected ...
Antonelli, Alessandro, Arcieri, Stefano, Baldini, Enke, Barollo, Susi, Carbotta, Giovanni, Catania, Antonio, Fallahi, Poupak, Mian, Caterina, Monti, Massimo, Palmieri, Andrea, Pironi, Daniele, Sorrenti, Salvatore, Tartaglia, Francesco, Tuccilli, Chiara, Ulisse, Salvatore, Vergine, Massimo   +15 more
core   +3 more sources